Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2966Carcinoma, Renal Cell 883Urinary Bladder Neoplasms 712Kidney Neoplasms 457Breast Neoplasms 408Neoplasms 390Neoplasm Metastasis 229Carcinoma, Non-Small-Cell Lung 229Lung Neoplasms 216Ovarian Neoplasms 211Colorectal Neoplasms 204Melanoma 195Carcinoma, Transitional Cell 190Testicular Neoplasms 171Pancreatic Neoplasms 142Sarcoma 129Head and Neck Neoplasms 121Colonic Neoplasms 120Wilms Tumor 119Uterine Cervical Neoplasms 116Stomach Neoplasms 98Neuroblastoma 90Multiple Myeloma 88Lymphoma, Non-Hodgkin 86Esophageal Neoplasms 86Lymphoma 83Carcinoma, Hepatocellular 81Carcinoma, Ovarian Epithelial 80Recurrence 75Squamous Cell Carcinoma of Head and Neck 74

Interventions

danusertib 1cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Metastatic Hormone Refractory Prostate Cancer × Genitourinary × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00766324 2014-05-28

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Nerviano Medical Sciences

Phase 2 Completed
118 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00636090 2013-12-04

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

Duke University

Completed
35 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡